Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
AstraZeneca
McKinsey
Daiichi Sankyo
Mallinckrodt
Cantor Fitzgerald
Accenture
Moodys
Johnson and Johnson

Generated: June 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,980,864

« Back to Dashboard

Summary for Patent: 5,980,864
Title: 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them
Abstract:1,4,7,10-Tetraazacyclodedecane butyltriols of general formula I.sub.A ##STR1## in which R.sup.1 means hydrogen or a metal ion equivalent independent of one another and R.sup.2 means a butyltriol radical as well as their salts with organic or inorganic bases or amino acids are valuable pharmaceutical agents.
Inventor(s): Platzek; Johannes (Berlin, DE), Gries; Heinz (Berlin, DE), Weinmann; Hanns-Joachim (Berlin, DE), Schuhmann-Giampieri; Gabriele (Berlin, DE), Press; Wolf-Rudiger (Berlin, DE)
Assignee: Schering Aktiengellsellschaft (Berlin, DE)
Application Number:07/671,041
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 5,980,864

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bayer Hlthcare GADAVIST gadobutrol SOLUTION;INTRAVENOUS 201277-006 Dec 18, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,980,864

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany40 09 119Mar 19, 1990

Non-Orange Book US Patents Family Members for Patent 5,980,864

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,399,043 1,4,7,10-Tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them ➤ Sign Up
6,951,639 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Cantor Fitzgerald
US Department of Justice
Cipla
Queensland Health
Dow
Merck
Moodys
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.